SG11202006935VA - Ghrelin o-acyltransferase inhibitors - Google Patents
Ghrelin o-acyltransferase inhibitorsInfo
- Publication number
- SG11202006935VA SG11202006935VA SG11202006935VA SG11202006935VA SG11202006935VA SG 11202006935V A SG11202006935V A SG 11202006935VA SG 11202006935V A SG11202006935V A SG 11202006935VA SG 11202006935V A SG11202006935V A SG 11202006935VA SG 11202006935V A SG11202006935V A SG 11202006935VA
- Authority
- SG
- Singapore
- Prior art keywords
- ghrelin
- acyltransferase inhibitors
- acyltransferase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201811004277 | 2018-02-05 | ||
| PCT/EP2019/052770 WO2019149959A1 (en) | 2018-02-05 | 2019-02-05 | Ghrelin o-acyltransferase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006935VA true SG11202006935VA (en) | 2020-08-28 |
Family
ID=65352017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006935VA SG11202006935VA (en) | 2018-02-05 | 2019-02-05 | Ghrelin o-acyltransferase inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11312709B2 (en) |
| EP (1) | EP3749304A1 (en) |
| AU (1) | AU2019213478A1 (en) |
| CA (1) | CA3089666A1 (en) |
| IL (1) | IL276439A (en) |
| SG (1) | SG11202006935VA (en) |
| WO (1) | WO2019149959A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122754A1 (en) * | 2021-12-23 | 2023-06-29 | The Scripps Research Institute | Processes and intermediates for preparing gb13, gb22 and himgaline |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2440541A1 (en) * | 2009-06-09 | 2012-04-18 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
| WO2013125732A1 (en) * | 2012-02-24 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| US8642585B2 (en) | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| EP3036237A4 (en) * | 2013-08-23 | 2017-01-25 | Fujian Haixi Pharmaceuticals Co. Ltd | Carboxylic acid compounds in treatment of diabetes mellitus |
-
2019
- 2019-02-05 AU AU2019213478A patent/AU2019213478A1/en not_active Abandoned
- 2019-02-05 CA CA3089666A patent/CA3089666A1/en active Pending
- 2019-02-05 WO PCT/EP2019/052770 patent/WO2019149959A1/en unknown
- 2019-02-05 SG SG11202006935VA patent/SG11202006935VA/en unknown
- 2019-02-05 US US16/967,262 patent/US11312709B2/en active Active
- 2019-02-05 EP EP19703981.1A patent/EP3749304A1/en not_active Withdrawn
-
2020
- 2020-08-02 IL IL276439A patent/IL276439A/en unknown
-
2022
- 2022-03-24 US US17/703,891 patent/US20220213076A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL276439A (en) | 2020-09-30 |
| US20220213076A1 (en) | 2022-07-07 |
| US11312709B2 (en) | 2022-04-26 |
| WO2019149959A1 (en) | 2019-08-08 |
| CA3089666A1 (en) | 2019-08-08 |
| EP3749304A1 (en) | 2020-12-16 |
| US20210053955A1 (en) | 2021-02-25 |
| AU2019213478A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| EP4076418A4 (en) | Sos1 inhibitors | |
| IL290341A (en) | Mta-cooperative prmt5 inhibitors | |
| IL277006A (en) | Cd73 inhibitors | |
| IL269196A (en) | Novel inhibitors | |
| EP4069212A4 (en) | Inhibitors of hif-2alpha | |
| IL304348A (en) | Cd73 inhibitors | |
| ZA202107835B (en) | Prc2 inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| ZA202109573B (en) | Prmt5 inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
| IL276439A (en) | Ghrelin o-acyltransferase inhibitors | |
| IL283112A (en) | Lox inhibitors | |
| GB201809295D0 (en) | Lox inhibitors | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201810765D0 (en) | SRPK1 inhibitors | |
| GB201721465D0 (en) | Inhibitors | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors |